Business Segments

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.

Our business is organized into three segments — North America, Europe and Rest of World. This reflects how we manage our global platform — as one business across all product and channel types.

North America

Our North America segment includes our operations in the United States and Canada.

Financial Contributions

In 2017, the North American segment accounted for approximately 42% of Mylan’s net third party sales. Read more about Mylan’s 2017 financial performance.

Highlights

In the U.S., the world’s largest pharmaceutical market, Mylan products fill one out of every 14 prescriptions dispensed – brand-name or generic. Our product sales are derived primarily from the sale of oral solid dosages, injectables, transdermal patches, gels, creams, ointments and unit dose offerings. In the U.S., we have one of the largest product portfolios among all generic pharmaceutical companies. We have a manufacturing and R&D footprint that extends across four states plus Puerto Rico. This includes Mylan’s largest oral solid dose facility in Morgantown, West Virginia, which operates roughly one million square feet of manufacturing space under one roof. We also have a long tradition of championing legislation to expand access to high quality medication.

In Canada, Saint-Hubert, Quebec, is home to one of our 10 global technology-focused development sites.

Access Channels

We leverage a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers.

These are relationships we've built and nurtured over decades. Because trust goes beyond our global quality standards. It's all about caring for the people helped by what we do. That's how we treat our partners as well. 

When you choose us as a partner, we make the relationship - and the shared value it creates - a priority. After all, it's important to us that you benefit from the work we do together.

If you dispense our difficult-to-manufacture and difficult-to-formulate products, you should know our commitment to producing them is long-term. Whether it's a medication for millions or for a handful of people, our priorities are to meet or exceed industry standards.

Europe

Our Europe segment comprises the company’s operations in countries across the continent, including notable positions in Germany, the U.K., France, Spain and Italy. Our presence continues to grow in several markets in Central and Eastern Europe, including Poland, Greece, the Czech Republic, Slovakia, Romania and Bulgaria.

Financial Contributions

In 2017, the Europe segment accounted for approximately 34% of Mylan’s net third party sales. Read more about Mylan’s 2017 financial performance.

 

Highlights

Europe represents the world’s second largest generic pharmaceutical market in terms of value. In France, Mylan stands out among its peers owning the biggest share of the generic segment. In Italy, we have the second highest market share in the generic prescription market in terms of volume and value.

In addition to being a leader in the generics pharmaceutical market throughout Europe, Mylan also holds a strong position in the branded products segment.

Mylan’s manufacturing network in Europe includes 11 facilities in France, Germany, Hungary, Ireland, Italy and Poland where we make a range of oral solid dose, injectable and complex products for markets around the world. Our European R&D presence includes six sites in Germany, Ireland, Italy and the U.K. Our manufacturing and R&D facilities in Europe are critical components of our larger, global network that works to ensure patients have access to the medicines they need.

Access Channels

We leverage a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers.

These are relationships we've built and nurtured over decades. Because trust goes beyond our global quality standards. It's all about caring for the people helped by what we do. That's how we treat our partners as well. 

When you choose us as a partner, we make the relationship - and the shared value it creates - a priority. After all, it's important to us that you benefit from the work we do together.

If you dispense our difficult-to-manufacture and difficult-to-formulate products, you should know our commitment to producing them is long-term. Whether it's a medication for millions or for a handful of people, our priorities are to meet or exceed industry standards.

Rest of World

Our Rest of World segment is made up primarily of our operations in Japan, Australia, China, Brazil, Russia, India, South Africa and certain markets in the Middle-East and South East Asia.

Financial Contributions

In 2017, the Rest of World segment accounted for approximately 24% of Mylan’s net third party sales. Read more about Mylan’s 2017 financial performance.

 

Highlights

India is home to nearly half of Mylan’s workforce and approximately half of its manufacturing facilities. Moreover, approximately a quarter of the company’s regulatory professionals and scientists are based in Hyderabad, where they work in one of Mylan’s global R&D centers. We also have a significant presence in Bangalore, which is where we have many injectables facilities and from which we manage our commercial activities, including our antiretroviral (ARV) and third-party active pharmaceutical ingredients businesses. Mylan’s robust commercial presence in India has made it the fastest growing multinational company in India with strong representation in therapeutic franchises such as hepatitis, oncology and critical care.

Since 2007, Mylan has been instrumental in increasing access to life-saving ARVs and has a majority market share in sub-Saharan African countries such as Zambia, Zimbabwe, Kenya, Nigeria and Cameroon. We are the number one provider of antiretroviral medicines in the developing world with a focus on Africa. Key to this achievement has been our success in introducing high quality USFDA-approved and WHO-prequalified products.

Mylan has been among the fastest growing companies in the Japan generics market for the last three years. We also maintain manufacturing capabilities in Japan, which play a key role in supplying our businesses throughout the country. Japan is the world’s third largest pharmaceutical market by value and the fifth largest generic prescription market by volume.

We hold a leading position in Australia's generic pharmaceuticals market, in terms of volume.

With our recent acquisition of Meda, we have accelerated our expansion in attractive emerging markets, such as China, Russia, South East Asia and the Middle-East.

Access Channels

We leverage a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers.

These are relationships we've built and nurtured over decades. Because trust goes beyond our global quality standards. It's all about caring for the people helped by what we do. That's how we treat our partners as well. 

When you choose us as a partner, we make the relationship - and the shared value it creates - a priority. After all, it's important to us that you benefit from the work we do together.

If you dispense our difficult-to-manufacture and difficult-to-formulate products, you should know our commitment to producing them is long-term. Whether it's a medication for millions or for a handful of people, our priorities are to meet or exceed industry standards.

  1. 0

    Governments

    Our government partners include the Indian National AIDS Control Organisation (NACO) and South Africa’s Department of Health. In India, we’re NACO’s leading supplier of HIV/AIDS medicines and help support its objective to halt and reverse the HIV/AIDS epidemic through integrated prevention, treatment and care and support programs. In South Africa, we’re also one of the leading suppliers of HIV/AIDS medicines.

    We also work with governments around the world through policy initiatives aimed at increasing generic utilization and improving access to high quality medicine.
  2. 0

    Physicians

    Hundreds of Mylan representatives call on thousands of physicians every day. Through these meetings, we’re better able to meet their needs and deliver on our commitment to provide physicians and their patients with access to high quality medicine.


    We also support physicians with initiatives like our Reassurance Program in India. This program helps patients with HIV/AIDS understand their condition and stay connected with their physicians between visits.
  3. 0

    Institutions

    Our institutional customers include a wide range of hospitals, long-term care facilities, correctional facilities, group purchasing organizations, integrated delivery networks and specialty pharmacies. We also work closely with many leading group purchasing organizations to ensure generic and brand name products are available to health care providers within the hospital environment.

    Our unique unit dose package formats include injectables, premixed mini-bags and single-dose and multi-dose vials. These packaging innovations help improve inventory control, reduce dispensing errors and promote the Rights of Medication Administration.


  4. 0

    Retailers

    We supply national and international chains as well as independent pharmacies. Our series of educational materials helps pharmacies empower their customers with information and answers about common conditions.
  5. 0

    Wholesalers

    Mylan’s worldwide relationships with wholesalers are vital to ensuring our products reach the people who need them in more than 165 countries and territories.
  6. Pharmacy Benefit Managers
    0

    Pharmacy Benefit Managers

    In the U.S., Mylan also works with pharmacy benefit managers (PBMs) to ensure patients have access to our high quality medicines through their health plans.